ada standards of care 2025 obesity pharmacotherapy glp-1 Framework for the pharmacological treatment and its complications from the European Association for the Study of Obesity (EASO) ada standards of care 2025

Abstract Any increase in alcohol use is associated with an increase in risk of illness and mortality and consequences of chronic alcohol use include cancer, hypertension, heart and liver disease, and Alcohol Use Disorder

Microdosing refers to starting at very low levels, often well below the typical therapeutic dose, and gradually building tolerance over time

To determine if GLP-1 medication is right for you, your doctor will consider the following: Body Mass Index (BMI) : If your BMI is 27 or higher with a weight-related condition like diabetes, hypertension, or sleep apnea, or 30 or higher without one

That suggests the issue may not be a class-wide GLP-1 problem, but rather specific to semaglutide drugs